International regulatory landscape and integration of corrective genome editing into in vitro fertilization

摘要: Genome editing technology, including zinc finger nucleases (ZFNs), transcription activator-like effector (TALENs), and clustered regularly interspaced short palindromic repeat (CRISPR)/Cas, has enabled far more efficient genetic engineering even in non-human primates. This biotechnology is likely to develop into medicine for preventing a disease if corrective genome integrated assisted reproductive represented by vitro fertilization. Although rapid advances are expected make germline gene correction feasible clinical setting, there many issues that still need be addressed before this could occur. We herein examine current status of mammalian embryonic stem cells zygotes discuss potential the international regulatory landscape regarding human modification. Moreover, we address some ethical social would raised when each country considers whether editing-mediated preventive should permitted.